RenovoRx, Inc. (RNXT): Nasdaq/NYSE listing notice — RenovoRx receives Nasdaq delisting notice for equity deficiency; COO resigns, new Chief Clinical Officer appointed
RenovoRx, Inc.
Nasdaq notified RenovoRx on Feb 21, 2024 that it failed minimum stockholders' equity of $2.5M; delisting proceedings to begin unless hearing requested.
Company plans to request hearing, which will stay delisting pending panel decision; previously raised ~$6.1M in private placement to bolster equity.
Chief Operating Officer Angela Gill Nelms resigned effective March 1, 2024 for personal reasons, no disagreement with company.
Board appointed Leesa Gentry, current SVP Clinical Operations, as Chief Clinical Officer effective March 1, 2024, assuming clinical/regulatory duties.
On February 22, 2024, the Company’s board of directors (the “Board”), by unanimous written consent to action, appointed Leesa Gentry, the Company’s current Senior Vice President of Clinical Operations, to the position of Chief Clinical Officer of the Company, effective March 1, 2024.
On February 16, 2024, Angela Gill Nelms provided written notice to the Company of her resignation as the Company’s Chief Operating Officer, effective March 1, 2024.
Key facts
Extracted from this filing and checked against the source text.
RenovoRx, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
Exchange
nasdaq
Notice
deficiency notice
Deficiency
stockholders equity
Rules
5550(b)(1)
Exact text from the filing
February 21, 2024, the Company received a written notice (the “Notice”) from Nasdaq that the Company had, as of the date of the Notice, failed to meet the Minimum Stockholders’ Equity Requirement and that Nasdaq would commence delisting proceedings against the Company unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Hearing Panel”). The Company plans to request a hearing, which request will stay any delisting or suspension action by the Nasdaq staff at least pending the issuance of the Hearing’s Panel decision and the expiration of any extension that may be gr
Leesa Gentry was appointed as Chief Clinical Officer at RenovoRx, Inc..
Action
appointed
Role
Chief Clinical Officer
Exact text from the filing
On February 22, 2024, the Company’s board of directors (the “Board”), by unanimous written consent to action, appointed Leesa Gentry, the Company’s current Senior Vice President of Clinical Operations, to the position of Chief Clinical Officer of the Company, effective March 1, 2024.
Angela Gill Nelms resigned as Chief Operating Officer at RenovoRx, Inc..
Action
resigned
Role
Chief Operating Officer
Exact text from the filing
On February 16, 2024, Angela Gill Nelms provided written notice to the Company of her resignation as the Company’s Chief Operating Officer, effective March 1, 2024.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.